Sulbactam

Summary

Sulbactam (CHEMBL403) is an approved small molecule (ATC J01CG01); indicated across 6 conditions including bacterial infectious disease and urinary tract infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01CG01
• Indications: 6 conditions
• Clinical trials: 16
• Chemistry: 233.24 Da · C8H11NO5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL403
Name	Sulbactam
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	130313
ChEBI	CHEBI:9321
ATC	J01CG01
Molecular formula	C8H11NO5S
Molecular weight	233.24
InChIKey	FKENQMMABCRJMK-RITPCOANSA-N

SMILES: CC1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)C

IUPAC name: (2S,5R)-3,3-dimethyl-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

Also known as: CP-458992, NSC-759886, Sulbactam, sulbactam, Salbactam, SID47193857, SID144207191, SID174006239, SID170465248, SID29215246, SULBACTAM, C0088545

Parent form; salt/anhydrous children: CHEMBL1200944, CHEMBL3989650

Patent coverage: 5,197 distinct patent families (15,874 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Beta-lactamase, Estrogen receptor, Beta-lactamase TEM, Beta-lactamase TEM, Beta-lactamase, Beta-lactamase, Beta-lactamase OXA-1, Beta-lactamase, Beta-lactamase 1, Beta-lactamase SHV-1.

Bioactivity

ChEMBL activities: 13 potent at pChembl ≥ 5 of 23 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P62593	6.1	Ki	800	nM	CHEMBL_ACT_1166898
P62593	6.1	IC50	800	nM	CHEMBL_ACT_581342
P05364	6	IC50	1000	nM	CHEMBL_ACT_581341
P62593	5.97	IC50	1066	nM	CHEMBL_ACT_17702875
P62593	5.85	IC50	1400	nM	CHEMBL_ACT_1000635
P62593	5.85	IC50	1400	nM	CHEMBL_ACT_1103431
P62593	5.85	IC50	1400	nM	CHEMBL_ACT_191821
P05364	5.85	IC50	1400	nM	CHEMBL_ACT_274487
ESR1	5.45	AC50	3512	nM	CHEMBL_ACT_25139362
P0AD63	5.41	IC50	3915	nM	CHEMBL_ACT_17702874
P00807	5.19	IC50	6500	nM	CHEMBL_ACT_922458
P62593	5.14	IC50	7300	nM	CHEMBL_ACT_2125194
P62593	5	IC50	10000	nM	CHEMBL_ACT_922455

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
urinary tract infection	3	MONDO:0100338	EFO:0003103
cleft palate	2	MONDO:0016064	HP:0000175
chorioamnionitis	2	MONDO:0000409	EFO:0009948
osteomyelitis	0	MONDO:0005246	EFO:0003102

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE4	7
PHASE3	4
PHASE1	3
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06440304	PHASE4	RECRUITING	Therapeutic Options for CRAB
NCT07004049	PHASE4	RECRUITING	Optimising TREATment for Severe Gram-Negative Bacterial Infections
NCT00137007	PHASE4	COMPLETED	Zithromax EV in Community-Acquired Pneumonia (CAP)
NCT00356148	PHASE4	COMPLETED	The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients.
NCT00952796	PHASE4	COMPLETED	A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections
NCT02688322	PHASE4	COMPLETED	Pharmacodynamics Modeling to Optimize Dosage Regimens of Sulbactam in Patients With Acinetobacter Infections
NCT03560232	PHASE4	TERMINATED	Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens
NCT01045902	PHASE3	COMPLETED	BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia
NCT02007603	PHASE3	COMPLETED	Concentration of Ampicillin / Sulbactam and Amoxicillin / Clavulanic Acid in the Blood During Renal Replacement Therapy in Longterm Renal Replacement Therapy Patients
NCT03477422	PHASE3	COMPLETED	CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria
NCT03894046	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
NCT07485010	PHASE2	NOT_YET_RECRUITING	Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
NCT06801223	PHASE1	RECRUITING	A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection
NCT02971423	PHASE1	COMPLETED	Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects
NCT03303924	PHASE1	COMPLETED	Study to Determine and Compare Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Subjects
NCT00463762	Not specified	WITHDRAWN	Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).